You are here: Industry Insights > Shire

News List

Shire’s $2.4bn oncology sell-off seen as Takeda spoiler pharmaphorum
April 17, 2018
Shire is to sell its oncology business to France’s Servier for $2.4 billion, in a move seen as a deterrent to a takeover by Takeda.
Shire Sells Oncology Business to France’s Servier for $2.4 Billion biospace
April 17, 2018
Only a couple weeks after Takeda Pharmaceuticals announced it was interested in buying Shire, Shire sells its oncology business to France’s Servier for $2.4 billion.
Takeda looks for loans to fund $40bn Shire takeover pharmaphorum
April 13, 2018
Takeda appears to be preparing its bid for rare diseases pharma Shire, reportedly sounding out major creditors for loans to finance the deal of up to $40 billion.
Takeda CEO Discusses Potential Shire Deal in Closed-Door Meeting With Analysts biospace
April 08, 2018
Shares of Shire Plc spiked overnight after increased rumors that Japanese pharma giant Takeda could be closer to making a deal to acquire the rare disease company.
Shire's investigational HAE treatment lanadelumab accepted for review by regulators in EU, Canada firstwordpharma
March 30, 2018
Shire announced Thursday that the European Medicines Agency has determined there is sufficient data to begin an accelerated assessment of its marketing application for the plasma kallikrein inhibitor lanadelumab.
EU ready to review Shire’s lanadelumab for HAE pharmatimes
March 30, 2018
EU regulators have validated Shire’s application to market its experimental hereditary angioedema (HAE) drug lanadelumab, indicating that there is sufficient data to begin a priority review.
The Big Tease: Takeda Considers Buying Shire biospace
March 29, 2018
Shire stock prices jumped up to 26 percent on rumors that Takeda Pharmaceuticals was considering a buyout.
Shire links with NanoMedSyn to work on new ERT pharmatimes
March 27, 2018
Shire has linked with US biotech NanoMedSyn to evaluate a potential enzyme replacement therapy (ERT) for an undisclosed lysosomal storage disorder.
Shire’s constipation drug under US review pharmatimes
March 07, 2018
Shire’s prucalopride is being assessed by regulators in the US as a treatment for chronic idiopathic constipation (CIC).
Shire Snaps Up Rights to a Preclinical Autoimmune Candidate for Undisclosed Sum biospace
January 31, 2018
Rare disease giant Shire plc plunked down an undisclosed sum to get its hands on a preclinical autoimmune drug candidate being developed by AB Biosciences.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page